メインコンテンツに移動


CPHI China 2025

Reimagine API sourcing with us— efficient, effortless, future-proof.

Meet us at Hall E1 Booth H28
24-26 June 2025
SNIEC, Shanghai, China
Schedule a meeting
Verified

Our Team at CPHI China 2025

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API  business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

  • 250+ APIs

  • 8 Manufacturing sites

  • 1970+ drug master files across global markets.

  • Over 325 ANDAs

  • Filed 4500+ patents globally, out of which 1125 have been granted.

  • Experience with complex APIs and formulations supporting early market entries.

  • Preferred pharma API supplier for pharma companies in more than 80 countries.

Sustainability

Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.

What we achieved in the past year:

 
 

Our Achievement (awards)

Our Plants

About CPHI China 2025

This premier event brings together over 3,500+ exhibiting companies, 90,000+ pharma professionals, and the latest innovations across pharmaceutical ingredients, contract manufacturing, biopharma, packaging, drug delivery systems, and more. It's where key industry players meet to explore new opportunities, deepen existing partnerships, and stay ahead of fast-evolving market demands.

As part of this dynamic ecosystem, we’re looking forward to engaging with peers, partners, and potential collaborators. Whether you're looking to streamline your API sourcing, improve supply chain efficiency, or explore strategic synergies—we’re open to conversations that create value.

If you're attending CPHI China, we’d love to connect.Let’s discuss how we can support your growth with smarter, simpler, and future-ready sourcing solutions.

Company

Contact Us

 

Follow Us on

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

© 2025 Dr. Reddy’s Laboratories Ltd. All rights reserved.

免責事項

このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。

X

Let’s talk API sourcing live at

Tackle sourcing bottlenecks and compliance hurdles

Hall E1 Booth H28 24-26 June 2025, Shanghai

Book a Meeting